Herman Burger

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
  2. doi request reprint Drug transporters of platinum-based anticancer agents and their clinical significance
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Drug Resist Updat 14:22-34. 2011
  3. pmc Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
    H Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Br J Pharmacol 159:898-908. 2010
  4. ncbi request reprint Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:1270-4. 2005
  5. ncbi request reprint Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Daniel den Hoed Kliniek Josephine Nefkens Institute, Rotterdam, The Netherlands
    Blood 104:2940-2. 2004
  6. ncbi request reprint Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens
    H Burger
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Building Room Be420, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 39:793-9. 2003
  7. ncbi request reprint Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:747-52. 2005
  8. ncbi request reprint Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill
    Paul W Schenk
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Josephine Nefkens Building room Be422, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Pharmacol 64:259-68. 2003
  9. ncbi request reprint Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:943-9. 2006
  10. doi request reprint Drug transporters and imatinib treatment: implications for clinical practice
    Karel Eechoute
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:406-15. 2011

Collaborators

Detail Information

Publications27

  1. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
    ..A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a 3-week-on/1-week-off dosing schedule...
  2. doi request reprint Drug transporters of platinum-based anticancer agents and their clinical significance
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Drug Resist Updat 14:22-34. 2011
    ..In addition, transporter-mediated tumour resistance, the impact of potential platinum transporter-mediated drug-drug interactions, and the role of drug transporters in the renal elimination of platinum compounds are discussed...
  3. pmc Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
    H Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Br J Pharmacol 159:898-908. 2010
    ..As decreased drug accumulation is a key mechanism of platinum resistance, SLCs may also contribute to the development of resistance. Here, we define the role of hSLC22A2 (OCT2) in the cellular uptake of platinum compounds...
  4. ncbi request reprint Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:1270-4. 2005
    ..The latter may imply that these wild-type c-KIT and PDGFR tumor types will probably not benefit from imatinib treatment...
  5. ncbi request reprint Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Daniel den Hoed Kliniek Josephine Nefkens Institute, Rotterdam, The Netherlands
    Blood 104:2940-2. 2004
    ..Since BCRP is highly expressed in the gastrointestinal tract, BCRP might not only play a role in cellular resistance of tumor cells but also influence the gastrointestinal absorption of imatinib...
  6. ncbi request reprint Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens
    H Burger
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Building Room Be420, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 39:793-9. 2003
    ..Apparently, c-KIT oncoprotein expression in SCLC was not correlated with activating mutations in c-kit exon 11. In analogy to GISTs, our results could imply that SCLC patients would not benefit from treatment with STI571...
  7. ncbi request reprint Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:747-52. 2005
    ....
  8. ncbi request reprint Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill
    Paul W Schenk
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Josephine Nefkens Building room Be422, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Pharmacol 64:259-68. 2003
    ....
  9. ncbi request reprint Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:943-9. 2006
    ..In conclusion, we generated an A2780 subline that showed a uniquely stable platinum resistance phenotype, which could theoretically be caused by an impaired inward transporter specific for cis-configurated platinum compounds...
  10. doi request reprint Drug transporters and imatinib treatment: implications for clinical practice
    Karel Eechoute
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:406-15. 2011
    ..In addition, more pharmacogenetic studies will be needed to validate associations...
  11. ncbi request reprint RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003
    ..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
  12. ncbi request reprint Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, The Netherlands
    Cell Cycle 3:1502-5. 2004
    ..Our findings may have serious implications for the chronic imatinib treatment of cancer patients...
  13. ncbi request reprint Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype
    Paul W Schenk
    Department of Medical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Mol Pharmacol 61:659-66. 2002
    ..Disruption of the S. cerevisiae SKY1 gene would thus result in deregulation of such mechanisms and, consequently, lead to altered drug sensitivity...
  14. doi request reprint Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
    Maja J A de Jonge
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    Eur J Cancer 46:3016-21. 2010
    ..v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers...
  15. doi request reprint Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors
    Ferry A L M Eskens
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:7156-63. 2011
    ..To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor...
  16. ncbi request reprint Effect of ABCG2 genotype on the oral bioavailability of topotecan
    Alex Sparreboom
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:650-8. 2005
    ..0% versus 31.4%; p = 0.037). It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates...
  17. pmc Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
    I R H M Konings
    Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, P O Box 2040, Rotterdam 3000 CA, The Netherlands
    Br J Cancer 103:987-92. 2010
    ..This phase I, accelerated titration study assessed maximum tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327...
  18. pmc A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    F A L M Eskens
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Br J Cancer 98:80-5. 2008
    ..No partial or complete responses were observed, stable disease lasting more than four cycles was seen in seven patients. The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD...
  19. ncbi request reprint SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line
    P W Schenk
    Department of Medical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Cancer Res 61:6982-6. 2001
    ..Our new findings strongly suggest that SRPK1 is involved in cisplatin-induced cell kill and indicate that SRPK1 might potentially be of importance for studying clinical drug resistance...
  20. pmc The spliceosome as target for anticancer treatment
    R J van Alphen
    Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Br J Cancer 100:228-32. 2009
    ..Alternative) Splicing events may play an essential role in tumourigenesis. The recent discovery that the spliceosome is a target for novel compounds with anticancer activity opens up new therapeutic avenues...
  21. pmc Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line
    K Nooter
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    Br J Cancer 71:556-61. 1995
    ....
  22. ncbi request reprint Interleukin-3 treatment of rhesus monkeys leads to increased production of histamine-releasing cells that express interleukin-3 receptors at high levels
    F C van Gils
    Department of Hematology, Erasmus University, Rotterdam, The Netherlands
    Blood 86:592-7. 1995
    ..It also indicates that IL-3, in addition to its direct effects on hematopoietic cells, may also stimulate hematopoiesis through the release of secondary mediators such as histamine by IL-3-responsive mature cells...
  23. ncbi request reprint Molecular evolution of interleukin-3
    H Burger
    Department of Medical Oncology, Dr Daniel den Hoed Cancer Center Dijkzigt, University Hospital Rotterdam, The Netherlands
    J Mol Evol 39:255-67. 1994
    ..3 cell-surface receptor. Insight into IL-3 architecture and structural analysis of the IL-3 receptor are needed to analyze the unusually fast evolution of IL-3 in more detail...
  24. pmc Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee
    A G Uitterlinden
    Department of Internal Medicine III, Erasmus University Medical School, 3000 DR Rotterdam, The Netherlands
    J Clin Invest 100:259-63. 1997
    ..e., the collagen type IIa1 gene encoding the most abundant protein in cartilage, might contribute to the association...
  25. pmc Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines
    H Burger
    Department of Medical Oncology, University Hospital Rotterdam and Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 77:1562-7. 1998
    ....
  26. doi request reprint Interaction of imatinib with human organic ion carriers
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphia, TN 38105, USA
    Clin Cancer Res 14:3141-8. 2008
    ..Here, we characterized the contribution of solute carriers to imatinib transport in an effort to further understand mechanisms involved in the intracellular uptake and retention (IUR) of the drug...
  27. ncbi request reprint Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
    Erin R Gardner
    Clinical Pharmacology Research Core, SAIC Frederick, Frederick, USA
    Clin Pharmacol Ther 80:192-201. 2006
    ....